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ABSTRACT 
Neuropathic pain occurs after peripheral nerve damage, inflammation or infection. In this situation, microglial 
cells become activated and play a key role in producing pain. Minocycline (microglia inhibitor), was reported to 
reduce pain when used preventively. However, it seems that, when used after nerve injury, results in its pain 
reducing effects are different. In this regard, to assess the pain reducing differences of minocycline, neuropathic 
pain was induced by the ligation of the sciatic nerve in the rat which is recognized as chronic constriction injury 
(CCI) and minocycline was administered before and after sciatic nerve injury. Wistar male rats (200-250 g, n=6) 
were used in these experiments. Rats were distributed in various groups: vehicle-treated CCI (control), sham-
operated and minocycline-treated CCI groups. In the first part of the experiment (pre-injury study), minocycline 
(10, 20, 30 and 40 mg/kg,) was injected one hour before surgery and then daily for two weeks. In the second part 
(post injury study), minocycline was administered: 1: at day one after nerve damage once a day to day 14, 2: at 
day seven after surgery and continued daily until day 14. Analgesimeter for thermal hyperalgesia and von Frey 
hairs for mechanical allodynia were used to evaluate pain behavior. Thermal hyperalgesia and mechanical allo-
dynia were attenuated significantly, when minocycline used before surgery, while it was not able to reduce pain 
behavior administered after surgery. It seems that, in spite of what some previous studies have reported, here, 
minocycline is not able to attenuate established neuropathic pain.  
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INTRODUCTION 
 
Neuropathic pain arising from functional 
changes in the pain sensory systems follow-
ing damage to the nerve, affects millions of 
people worldwide (Tsuda et al., 2005). Cur-
rently, treatment of this prevalent condition is 
not satisfactory (Zimmermann, 2001). To 
date, there is no clear mechanism underlying 
neuropathic pain. Common analgesic drugs, 
like anti-inflammatory drugs and opioids, are 
used to reduce neuropathic pain, but in some 
patients, they are not effective and require 
high dosages which can cause unacceptable 
side effects (Wang et al., 2011). 
EXCLI Journal 2017;16:229-235 – ISSN 1611-2156 
Received: June 06, 2016, accepted: February 09, 2017, published: March 08, 2017 
 
 
 
230 
Microglia are increasingly considered as a 
crucial factor in the appearance of neuro-
pathic pain after damage to the peripheral 
nerve (Xiaodi et al., 2010). Microglia marker 
expression, proliferation and morphological 
changes were seen following sciatic nerve in-
jury, chronic constriction injury (CCI) and 
sciatic nerve ligation (SNL) (Echeverry et al., 
2008). Minocycline which is considered as an 
inhibitor of microglial cells, has no effect on 
neurons and astrocytes (Tikka and 
Koistinaho, 2001). So far, the effects of mino-
cycline on neuropathic pain have been 
evaluated in many experiments (Guasti et al., 
2009; Ledeboer et al., 2005; Padi and 
Kulkarni, 2008; Raghavendra et al., 2003; 
Zanjani et al., 2006). In this situation, some 
studies have shown that minocycline can 
exert an anti-allodynic and anti-hyperalgesic 
effect when administered before nerve injury. 
Nevertheless, some other reports indicate that 
minocycline cannot reduce pain behavior 
after damage to peripheral nerves (Guasti et 
al., 2009; Padi and Kulkarni, 2008; 
Raghavendra et al., 2003; Zanjani et al., 
2006). On the other hand, some additional 
studies suggest that minocycline administered 
post-injury is effective in decreasing pain be-
havior (Ledeboer et al., 2005; Mei et al., 
2011; Nazemi et al., 2012). 
As is reported in the literature, it is well 
recognized that minocycline can decrease 
neuropathic pain (when administered before 
nerve damage), yet experiments about such 
effect after the commencement of nerve dam-
age are controversial. In this regard, in clini-
cal practice, the benefit of using minocycline 
should logically be after nerve damage. 
Therefore, this experiment was designed to 
re-assess the effect of minocycline on the 
chronic pain model of CCI, when injected be-
fore and also after nerve damage. 
 
MATERIAL AND METHODS 
Animals 
In this study, male Wistar rats, aged 3 
months (weighing 200-250 g, n = 6) were 
used. Animals were permitted to accustom to 
the housing facilities one week before the be-
ginning of the experiments.  A quiet room was 
chosen for the behavioral studies which were 
performed between the hours of 8:00 and 
12:00 AM. The ethical guidelines of the Inter-
national Association for the Study of Pain 
(IASP) throughout the experiment were 
considered (Zimmermann, 1983). 
 
Surgery 
CCI model of neuropathic pain was 
produced according to Bennett and Xie model 
(Bennett and Xie, 1988). Ketamine (60 
mg/kg) and xylazine (10 mg/kg) were used to 
anesthetize the animals. After exposing, the 
left sciatic nerve was tied loosely with four 
ligatures by chromic cat gut 4-0 thread around 
the nerve close to the trifurcation with 1 mm 
space. After irrigation with normal saline, the 
wound was closed in layers using 4-0 silk 
thread and surgical skin staples. Rats in sham-
operated group experienced surgical 
procedure, but the ligation was not tied. 
 
Drug preparation 
Saline solution (0.9 % NaCl) was used as 
a solvent for minocycline (Sigma, USA). The 
animals were anesthetized with Ketamine/ 
Xylazine mixture (60/10 mg/kg) injected in-
traperitoneally (i.p.). 
 
Drug administration 
In this study, two main groups of rats were 
designed as pre-surgery and post-surgery 
groups. Each main group was divided into 
three subgroups: I) vehicle-treated CCI (con-
trol) group, II) sham-operated (sham) group 
and III) minocycline-treated CCI (minocy-
cline) group. Control and Sham animals re-
ceived saline as a vehicle. In the preventive 
study, animals received minocycline (10, 20, 
30, and 40 mg/kg) 1 h before surgery and con-
tinued daily until day 14 post-surgery 
(Raghavendra et al., 2003). In the post-
surgery study, Group 1: rats received 
minocycline (10, 20, 30, and 40 mg/kg) at 
day1 post-surgery and continued daily to day 
14. Group 2: rats received minocycline (10, 
20, 30, and 40 mg/kg) at day 7 post-surgery 
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and continued daily to day 14. In the preven-
tive study, all behavioral tests performed on 
day 0 which was considered as a control day 
and continued on days 1, 3, 5, 7, 10, and 14 
after nerve ligation. In the post-surgery study, 
in group 1, behavioral tests were performed at 
days 0, 1, 3, 5, 7, 10 and 14, and in group 2, 
behavioral tests were done at days 0, 7, 10, 
and 14 after nerve damage. 
 
Behavioral tests and experimental design 
Noxious and innocuous stimuli were used 
for evaluating of the sciatic nerve sensitivity. 
Animals were placed into the chambers 
30 min before testing to accustomed to the 
testing chambers. Hyperalgesia and allodynia 
were evaluated in animals. The order of be-
havioral tests was thermal hyperalgesia and 
mechanical allodynia, 30 min was considered 
between each assay. 
 
Thermal hyperalgesia 
Hargreaves test was used for the assess-
ment of thermal hyperalgesia (Hargreaves et 
al., 1988). A beam of radiant heat was focused 
on the plantar surface of the left paw through 
a transparent Perspex surface (Ugo Basile, 
Comerio, Italy). The withdrawal latency was 
recorded with a cut-off time of 20 s to prevent 
tissue damage. The left paw was tested five 
times, and 5 min was considered as an interval 
between each test. The average value of the 
withdrawal latency of five consecutive tests 
was recorded. 
 
Mechanical allodynia 
A set of calibrated nylon monofilaments 
(Stoelting, USA) was applied to measure me-
chanical sensitivity to non-noxious stimuli. 
For the assessment of mechanical sensitivity, 
von Frey test was performed (Chaplan et al., 
1994). A transparent plexiglass cage on an el-
evated metal screen surface with 1 cm mesh 
openings was used. The left hind paw of each 
animal was exposed to the increasing inten-
sity of von Frey filaments sequentially. The 
paw withdrawal threshold was considered as 
the lowest von Frey stimulus eliciting two se-
quential responses with 3 min intervals be-
tween them (withdrawal from pressure). In-
creasing stimuli from 2 to 60 g were delivered 
to the plantar surface of the paw using succes-
sively greater diameter filaments until the 
hind paw was withdrawn. In the absence of a 
response, to avoid tissue damage, 60 g was 
considered as the cut-off point.  
 
Statistical analysis 
One-way repeated measures analysis of 
variance (RM-ANOVA), followed by a post-
hoc Tukey's test was used to analyze the par-
ametric data. Related samples followed by the 
Wilcoxon test was used to analyze the non-
parametric data. In all cases, data expressed 
as mean ± SEM (standard error) and P-values 
less than 0.05 were considered significant. 
Data were analyzed using the statistical pack-
age “SPSS 18”. 
 
RESULTS 
Effect of preventive administration of  
minocycline on pain behaviors in thermal 
hyperalgesia test  
Minocycline (10, 20, 30, and 40 mg/kg) 
decreased thermal hypersensitivity in the 
drug-treated CCI group during the period of 
study when compared to day 0. Minocycline 
10 and 20 mg/kg decreased pain in days 10 
and 14, while with the dosages of 30 and 40 
mg/kg a decrease in pain behavior was started 
at day one and this effect was continued until 
day 14 compared to day 0. A significant de-
crease in pain behavior was found by minocy-
cline 10 mg/kg in comparison to vehicle-
treated CCI animals (P<0.001) which was in-
itiated from day 3 and continued to day 14. 
On the other hand, in comparison to vehicle-
treated CCI group, minocycline 20, 30, and 40 
mg/kg alleviated the pain behavior one day 
after the nerve damage which was continued 
throughout the study period. Vehicle-treated 
CCI group showed thermal hyperalgesia 
(P<0.01) at the first day following nerve in-
jury, which was sustained throughout the ex-
perimental period. Sham-operated rats did not 
show pain behavior during the 14 days of the 
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study compared to the control day (Figure 
1A).  
In mechanical allodynia test, vehicle-
treated CCI group showed allodynia one day 
following nerve ligation (P<0.05) compared 
to day 0, this effect continued until the end of 
the study. Compared to day 0, minocycline 
with the different dosages controlled the allo-
dynic pain. The pain reducing effects of mino-
cycline 30 and 40 mg/kg was seen one day af-
ter nerve ligation while these effects, with 
dosages of 10 and 20 mg/kg were appeared at 
days 7 and 5 following nerve injury respec-
tively. Furthermore, minocycline (10, 20, 30, 
and 40 mg/kg) showed anti-allodynic effects 
in comparison to vehicle-treated CCI rats 
(P<0.001). Sham-treated animals did not pro-
duce allodynic pain compared to day 0 before 
surgery (Figure 1B).   
 
 
Figure 1: Effect of pre-injury administration of minocy-
cline in various treatment days on thermal hyperalgesia 
and mechanical allodynia. Minocycline (10, 20, 30 and 
40 mg/kg; i.p.) from day 0 before nerve injury to day 14 
was injected, and paw withdrawal latency (A) and paw 
withdrawal threshold (B) were measured. Data were 
shown as mean ± S.D. 
 
Effect of post-injury administration of 
minocycline on pain behaviors 
Group 1: Daily administration of minocy-
cline (10, 20, 30, and 40 mg/kg) from day one 
to day 14 in the post-injury model, had no ef-
fects in decreasing pain behaviors in response 
to thermal and mechanical stimuli respec-
tively (Figure 2A, 2B).  
Group 2: Daily administration of minocy-
cline (10, 20, 30, and 40 mg/kg) at day seven 
to day 14 in the post-injury model, had no ef-
fects in reducing pain behaviors in response 
to thermal and mechanical stimuli respec-
tively (Figure 2C, 2D).  
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Figure 2: Effect of minocycline on established thermal 
hyperalgesia and mechanical allodynia in various treat-
ment days. Minocycline (10, 20, 30 and 40 mg/kg; i.p.) 
was injected at day 1 and 7 and continued until day 14 
respectively.  Paw withdrawal latency in response to the 
beam of radiant heat (A, C) and paw withdrawal thresh-
old in response to Von Frey filaments (B, D) were as-
sessed. Data were presented as mean ± S.D.  
 
 
DISCUSSION 
In this study, the effects of minocycline on 
neuropathic pain before and after nerve dam-
age were assessed. The experiment was 
performed in two ways: pre and post-injury 
studies. We found that administration of 
minocycline before nerve injury attenuated 
pain sensitivity, while its use following nerve 
damage did not reduce already existing pain. 
To date, to create a model simulating neu-
ropathic pain in a human, various studies have 
been performed with a focus on damage to the 
sciatic nerve, in this regard, CCI is one of the 
models, which can produce significant pain in 
animals  (Mika et al., 2007). Data from the 
studies on chronic pain show an abnormal ex-
citability of the neurons in neuropathic pain. 
Following peripheral nerve injury in primary 
sensory ganglia and the dorsal horn of the spi-
nal cord some functional and anatomical al-
terations of neurons have been detected 
(Costigan et al., 2009). Apart from neurons, 
there are many data indicating these changes 
also arise in glial cells, particularly microglia 
(Scholz and Woolf, 2007). It is most likely 
that when neuropathic pain is produced by 
CCI, activation of spinal microglia plays the 
main role in this process. Moreover, neuro-
pathic pain can be controlled efficiently when 
these cells are inhibited (Mika et al., 2007; 
Raghavendra et al., 2003; Tsuda et al., 2005). 
It seems that there is a relationship between 
microglia activation, proinflammatory cyto-
kines and pain signaling pathways (Watkins 
and Maier, 2003). Furthermore, studies 
demonstrate that minocycline can protect 
neurons against traumatic brain injury and 
neurodegenerative diseases (Choi et al., 
2007). These effects strongly show that mi-
croglia activation is inhibited in these situa-
tions.   
Studies on minocycline mechanism of ac-
tion show that it inhibits MAP kinase pathway 
in microglia and can decrease their activities 
(Piao et al., 2006). Increasingly, experiments 
indicate that minocycline can attenuate pain 
when used before nerve injury (Guasti et al., 
2009; Padi and Kulkarni, 2008; Raghavendra 
et al., 2003; Zanjani et al., 2006). Although 
the majority of evidence emphasize on the ef-
fectiveness of this drug in reducing neuro-
pathic pain injected before nerve damage, 
nevertheless the results are strongly contra-
dictory when used at various times after nerve 
injury. It has been shown that, during a period 
of 14 days experimental studies, minocycline 
decreases pain hypersensitivity when admin-
istered one hour before nerve injury (Guasti et 
al., 2009; Zanjani et al., 2006). In another 
study, data show that minocycline relieves 
pain during ten days of the study when in-
jected preventively (Raghavendra et al., 
2003). In a 28 days experiment, it has also 
been shown, that, repeated administration of 
minocycline initiated 2 hours before nerve 
damage inhibits the development of mechan-
ical hypersensitivity until day 21 (Padi and 
Kulkarni, 2008). Similarly, we obtained same 
results concerning pain reducing effects of 
minocycline used preventively. 
However, there are different aspects of the 
effects of minocycline on neuropathic pain 
when administered following damage to neu-
rons or in already established pain. Many data 
indicate that minocycline cannot relieve the 
existing pain (Padi and Kulkarni, 2008; 
Raghavendra et al., 2003; Zanjani et al., 
2006). In this regard, one study shows that i.p. 
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administration of minocycline started at day 
five post-ligation until day 10, has not been 
able to attenuate existing hyperalgesia and al-
lodynia (Raghavendra et al., 2003). Another 
study reports that a single injection of mino-
cycline at day four throughout the progression 
of pain hypersensitivity has no effect on me-
chanical stimulation in the CCI model. This 
experiment has also indicated that 
minocycline, when used daily, from day 7 to 
day 28 post-ligation cannot decrease mechan-
ical stimulation during the period of the study 
(Padi and Kulkarni, 2008). In the present 
study, our data showed that, injection of 
minocycline at day 1 (continued daily to day 
14) and at day 7 (continued daily to day 14) 
after nerve damage, could not reduce 
allodynia and hyperalgesia which is in 
accordance with the results of some previous 
studies on minocycline administered after 
nerve damage. 
On the other hand, contrary to what men-
tioned above, there are some other reports in-
dicating that, minocycline can decrease pain 
when administered following damage to the 
nerve. It has been shown that a single dose of 
minocycline used post-nerve ligation, com-
pletely reverses pain behavior induced by 
SNL, in which the drug alleviates mechanical 
allodynia only at days 1, 3 and 7 and not on 
days 10 or 21 following nerve lesion (Mei et 
al., 2011). Another research indicates that 
chronic injection of minocycline for eight 
days initiated from day six following nerve li-
gation, the drug attenuates allodynia and hy-
peralgesia at day 13 postoperatively (Nazemi 
et al., 2012). Moreover, it has been shown that 
minocycline is able to attenuate the allodynia 
one day, but not one week following nerve li-
gation (Ledeboer et al., 2005). 
In conclusion, based on the analgesic ef-
fects of minocycline used pre and post nerve 
injury model and what we found in this re-
gard, it seems that there are some differences 
in minocycline action in relieving neuropathic 
pain which is needed more complementary 
studies to obtain a clear explanation in this 
field. In fact, as it was reported in the previous 
studies, our data supported the preventive use 
of minocycline in reducing pain hypersensi-
tivity behavior, but it failed to inhibit pain 
when used after an injury to the sciatic nerve 
in CCI model. However, we suggest that the 
evaluation of minocycline effects at different 
time points, dosages in different nerve injury 
models of neuropathic pain needs to be done 
after nerve damage to attain a comprehensive 
result for its possible use in already estab-
lished chronic pain in the clinic.  
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